Sponsors now have it in writing that including expanded access policies on their websites would not be considered off-label promotion by the US Food and Drug Administration.
The agency wrote in updated draft question-and-answer guidance on expanded access to investigational drugs that if a sponsor mentions...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?